RxDoctor Payments Data

Richard Winn

Infectious Disease · Lubbock, TXNPI 1073672994

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $24,075 of the $32,529 with a category attached, or 74.0%. AbbVie accounts for 89.8% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2020 at $13,462 and has fallen 99.4% since, to $83 in 2024. Among infectious disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$32,529in general payments, 2019–2025

Across 171 payments — averaging $190.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$29K
  • Viiv Healthcare Company$928
  • Astellas Pharma US Inc$502
  • Merck$438
  • Tetraphase Pharmaceuticals, Inc.$319
  • AstraZeneca$255
  • plus $886 from 9 others

What the payments were for

  • Speaking & faculty fees$24,07574%
  • Travel & lodging$3,76612%
  • Food & beverage$4,53714%
  • Education$1330%
  • Gifts$180%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$32,529 in reported general payments places this provider in the 90th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas →

Other infectious disease in Lubbock

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →